Application of matrine to medicament for treating or preventing enterovirus 71 type infection

A technology of enterovirus and matrine, which is applied in the field of medicine, can solve the problems that the mechanism has not been detailed, and the prevention and treatment effects have not been mentioned and applied, so as to improve the quality of treatment and drug compliance, reduce the pain of treatment, Tolerance-enhancing effects

Inactive Publication Date: 2011-11-16
WUHAN UNIV
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Although the antiviral effect of matrine on Coxsackie virus has been reported before, it has only been reported on the study of Coxsac...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of matrine to medicament for treating or preventing enterovirus 71 type infection
  • Application of matrine to medicament for treating or preventing enterovirus 71 type infection
  • Application of matrine to medicament for treating or preventing enterovirus 71 type infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] Drug toxicity test (MTT method)

[0053] After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. The drug was diluted step by step with cell culture medium. After dilution, add different concentrations of drugs into the cell culture wells where the supernatant was discarded, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no drugs, only culture medium), and then Add 100 μl of cell culture medium, place in a 37°C, 5% CO2 incubator, and cultivate for 48 hours, then add 20ul of MTT solution (5mg / ml prepared in PBS, pH=7.4) to each well. Continue to incubate for 4h, terminate the culture, be careful Aspirate and discard the culture supernatant in the well. For sus...

Embodiment 2

[0057] Determination of half infectious dose (TCID50) of EV71 on cells

[0058] Transfer the RD cells cultured into a single layer to a 96-well cell culture plate, and place them in a cell culture incubator for 18-24 hours. The virus liquid was serially diluted 10 times (10-1...10-8) with the maintenance solution. Discard the culture medium in each well of the RD cultured into a single layer, wash each well with PBS 3 times, add 100 μl of virus solution of different concentrations to each well, absorb at 37°C for 1.5 h, discard the virus dilution solution, and add 100 μl to each well Maintenance solution, 10 repetitions for each concentration, set normal cell control wells. The cytopathic changes (CPE) in each well were observed daily for 3 consecutive days, and the CPE conditions were recorded. The titer of the virus was then calculated by the following formula.

[0059] PD / [log(dilution above 50%)-log(dilution below 50%)]=[(%next above 50%)-50%] / [(%next above 50%)-(%n...

Embodiment 3

[0062] Antiviral Effect of Matrine on EV71

[0063] 1) Preventive effect of matrine on EV71 virus infection

[0064] After 24-48 hours of culture, when the RD cells are almost covered with a single layer, the culture medium is discarded, digested with trypsin, and transferred to a 96-well sterile cell culture plate, 100 μl per well. Place it in a cell culture incubator for 18-24 hours to make the cells grow into a single layer for later use. The drug was diluted step by step with cell culture medium. After dilution, add different concentrations of drugs into the cell culture wells where the supernatant was discarded, 100 μl per well, repeat 3 wells for each concentration, and set up cell control wells (no virus, no drug, only culture solution) and Virus control wells (without adding drugs, adding virus, and adding culture medium). After drug incubation for 1 hour, discard the supernatant, wash three times with PBS, add virus diluted with culture medium, 100 μl per well, inc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of matrine to a medicament for treating or preventing enterovirus 71 type infection. The invention proves that the matrine has good anti-virus effect in an in-vitro enterovirus 71 type (EV71) infection cell test. The matrine has certain killing effect on the EV71, can prevent EV71 infection, has good treatment effect on cells infected with EV71, and has good inhibition effect on virus replication, wherein the action effect is more remarkable than that of a positive control medicament ribavirin. In addition, the matrine has good inhibition effect on inflammatory reaction caused by EV71, so the medicament has a prospect of being developed into an anti-EV71 medicament.

Description

technical field [0001] The invention relates to the technical field of medicine, and more specifically relates to the application of matrine in a medicine for treating or preventing enterovirus 71 (EV71) infection. Background technique [0002] Enterovirus 71 (human enterovirus 71, EV71) is a member of the Picornaviridae Enterovirus genus and was first isolated in 1969 from fecal samples of infants with central nervous system diseases in California. Usually EV71 infection will cause hand, foot and mouth disease, which is mild and mostly self-limiting, which is difficult to distinguish from hand, foot and mouth disease caused by Coxsackie A16. In addition, EV71 can also cause aseptic meningitis, brainstem encephalitis, acute flaccid paralysis, acute cardiopulmonary dysfunction and other serious neurological diseases, and even death. In recent years, EV71 has repeatedly caused disease outbreaks or epidemics in the world. For example, large-scale EV71 outbreaks occurred in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4375A61P31/14A61P1/00A61P29/00
Inventor 吴建国张文婧邬开朗朱应金晶
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap